Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.41 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.41 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.41 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3659679 | 0.95 | ADORA3 (0.42) | ADORA3GRM5TARBP2CACNA1FCACNA1D | |
| SCHEMBL2781293 | 0.90 | TARBP2 (0.41) | ADORA3TARBP2CACNA1FCACNA1DCACNA1S | |
| SCHEMBL2780208 | 0.88 | TARBP2 (0.42) | ADORA3TARBP2CACNA1FCACNA1DCACNA1S | |
| SCHEMBL2777413 | 0.84 | ADORA3 (0.48) | ADORA3TARBP2CACNA1FCACNA1DCACNA1S | |
| SCHEMBL2776301 | 0.83 | TARBP2 (0.46) | ADORA3TARBP2CACNA1FCACNA1DCACNA1S | |
| SCHEMBL2774203 | 0.82 | TARBP2 (0.45) | ADORA3TARBP2CACNA1FCACNA1DCACNA1S | |
| SCHEMBL2776836 | 0.82 | KDM4E (0.46) | ADORA3TARBP2CACNA1FCACNA1DCACNA1S | |
| SCHEMBL2774268 | 0.81 | ALDH1A1 (0.47) | ADORA3TARBP2CACNA1FCACNA1DCACNA1S | |
| SCHEMBL2778440 | 0.81 | TARBP2 (0.43) | ADORA3TARBP2CACNA1FCACNA1DCACNA1S | |
| SCHEMBL2775921 | 0.80 | EGLN1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2227475-B1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | FIBROGEN INC (US) | 2014-02-19 | — | — | EP | disclosed |
| US-8269008-B2 | Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions | FIBROGEN, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100303928-A1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | FIBROGEN, INC. (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100303928-A1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | HIF1AN, HIF1A, EGLN2 | ADORA3 2518/4885GRM5 1898/4885TARBP2 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.